Cardiac and Pulmonary conditions are showing positive advancement in stem cell therapy treatments.

cardiac pulmonary

 

Asthma

Asthma is a common chronic inflammatory disease of the airways characterized by symptoms including wheezing, coughing, chest tightness, and shortness of breath, reversible airflow obstruction, and bronchospasm. Asthma is clinically classified according to the frequency of symptoms, forced expiratory volume in 1 second (FEV1), and peak expiratory flow rate. Asthma may also be classified as atopic (extrinsic) or non-atopic (intrinsic). It can be exercise induced or occupational. Asthma affects an estimated 300 million people worldwide and caused 250,000 deaths in 2009. Traditional management usually focuses on reduction to allergen exposure and medical therapy that consists of beta-2-agonists, anti-cholinergics, or inhaled corticosteroids.

lung healthResearch has been ongoing around the world that exploits the anti-inflammatory and immuno-modulatory properties of adult stem cells to control the reactive airways associated with asthma. The Cell Surgical Network is investigating the effects of SVF (rich in mesenchymal stem cells and growth factors) on chronic asthma. We use a protocol that includes a combination of intravenous and nebulized SVF delivery. The deployment protocol performed under local anesthesia is all done as an outpatient at the time of SVF harvesting and procurement. The entire cellular surgical procedure takes approximately 3 hours.

Have you had stem cell therapy to treat asthma? Fill out the brief form below to tell us about your experience:

Your Name (required)

Your Email (required)

Subject

Tell us about your asthma treatment experience

Post Myocardial Infarction (MI)

Myocardial Infarction (also known as heart attack) is responsible for significant cardiac destruction due to ischemia (lack of blood flow). This can lead to further or recurrent infarct and chronic angina. This problem is caused most commonly by coronary vessel disease which is very common in the United States and associated with significant morbidity.

Post Myocardial Infarction (MI) and Cell Surgical Network

dnaCell therapy potentially offers an important solution for chronic ischemia. During cardiac ischemia, millions of myocytes are lost resulting in loss of contractile function. One of the great goals of regenerative medicine is to engineer methods of replacing these cells. Bone marrow derived mesenchymal stem cells and now recently adipose derived mesenchymal stem cells appear to be playing an important role in this regeneration. There is also a growing body of data supporting the use of engineered biologics such as selected cell populations, organic scaffolds, and modified (differentiated or de-differentiated) stem cells to regenerate damaged myocardium. It is unknown whether the cost of engineered biologics over harvested stem cells is justified until long term studies are available. The results of clinical trials of the use of adult mesenchymal stem cells to treat cardiac disease have demonstrated safety and most have shown positive clinical results. Mesenchymal stem cells have been deployed intravenously, injected into the myocardium, and placed in the coronary arteries. It remains unclear if one delivery method is clearly superior to another. It is also unclear which source of mesenchymal cells is optimal for cardiac regeneration but adipose derived cells appear to be highly effective in this area.

Cell Surgical Network Call to Action

Research has been ongoing around the world that exploits the anti-inflammatory and regenerative properties of adult stem cells to mitigate cardiac ischemia. The Cell Surgical Network is investigating the effects of SVF (rich in mesenchymal stem cells and growth factors) on damaged myocardium. We use a protocol designed by our interventional cardiologist that includes intravenous deployment. The deployment protocol is performed under local anesthesia and is all done as an outpatient at the time of SVF harvesting and procurement. The entire cellular surgical procedure takes approximately 3 hours.

 

Congestive Heart Failure (CHF) and Cardiomyopathy

 

Congestive heart failure (CHF) is responsible for as many as one million hospitalizations in the U.S. annually and is considered the main cause or contributor to 53,000 deaths each year in the United States. CHF is associated with cardiomyopathy. Cardiomyopathy (deterioration in heart muscles) is commonly caused by coronary vessel disease but can also be due to infection and other causes. In this condition, the heart loses its ability to pump blood efficiently.

CHF and Cardiomyopathy and Cell Surgical Network

Cell therapy potentially offers an important solution for CHF and cardiomyopathy. During cardiac ischemia, millions of myocytes are lost resulting in loss of contractile function. One of the great goals of regenerative medicine is to engineer methods of replacing these cells. Bone marrow derived mesenchymal stem cells and now recently adipose derived mesenchymal stem cells appear to be playing an important role in this regeneration. There is also a growing body of data supporting the use of engineered biologics such as selected cell populations, organic scaffolds, and modified (differentiated or de-differentiated) stem cells to regenerate damaged myocardium. It is unknown whether the cost of engineered biologics over harvested stem cells is justified until long term studies are available. The results of clinical trials of the use of adult mesenchymal stem cells to treat cardiac disease have demonstrated safety and most have shown positive clinical results. Mesenchymal stem cells have been deployed intravenously, injected into the myocardium, and placed in the coronary arteries and it is still unclear if one delivery method is clearly superior to another. It is also unclear which source of mesenchymal cells is optimal for cardiac regeneration but adipose derived cells appear to be highly effective in this area.

Cell Surgical Network Center Call to Action

Research has been ongoing around the world that exploits the anti-inflammatory and regenerative properties of adult stem cells to mitigate heart failure. The Cell Surgical Network is investigating the effects of SVF (rich in mesenchymal stem cells and growth factors) on CHF. We use a protocol designed by our interventional cardiologist that includes intravenous deployment. The deployment protocol is performed under local anesthesia and is all done as an outpatient at the time of SVF harvesting and procurement. The entire cellular surgical procedure takes approximately 3 hours.

Asthma Degenerative Disease

Asthma is a common chronic inflammatory disease of the airways characterized by symptoms including wheezing, coughing, chest tightness, and shortness of breath, reversible airflow obstruction, and bronchospasm. Asthma is clinically classified according to the frequency of symptoms, forced expiratory volume in 1 second (FEV1), and peak expiratory flow rate.[3] Asthma may also be classified as atopic (extrinsic) or non-atopic (intrinsic). It can be exercise induced or occupational. Asthma affects an estimated 300 million people worldwide and caused 250,000 deaths in 2009. Traditional management usually focuses on reduction to allergen exposure and medical therapy that consists of beta-2-agonists, anti-cholinergics, or inhaled corticosteroids.

Asthma and Cell Surgical Network

Asthma research has been ongoing around the world and at Cell Surgical Network that exploits the anti-inflammatory and immuno-modulatory properties of adult stem cells to control the reactive airways associated with asthma. The Cell Surgical Network is investigating the effects of SVF (rich in mesenchymal stem cells and growth factors) on chronic asthma. We use a protocol that includes a combination of intravenous and nebulized SVF delivery. Subjective reports, changes in steroid use and pulmonary function tests help measure outcomes in a meaningful way.

Asthma Call to Action

We care about our Asthma patients at Cell Surgical Network and take pride in the time we provide to our patients to deploy the best protocols to help our patients achieve their goals. By filling out our Confidential Candidate Application, we will answer the questions and concerns you may have about Cell Surgical Network protocols for Asthma. Our Cell Surgical Network has Treatment Centers in several states. Locate the closest Treatment Center using Our Physician Network Map.

Lung Disease

Chronic Obstructive Pulmonary Disease (COPD)

Chronic obstructive pulmonary disease (COPD) is one of the most common lung diseases. It makes it difficult to breathe. There are two main forms of COPD: chronic bronchitis, which involves a long-term cough with mucus, and emphysema, which involves destruction of the lungs over time. Most people with COPD have a combination of both conditions. Smoking is the leading cause of COPD. Standard treatment includes the use of bronchodilator inhalers, steroids, and supplemental oxygen.

Chronic Obstructive Pulomany Disease (COPD) and Cell Surgical Network

Research has been ongoing around the world that exploits the anti-inflammatory and immuno-modulatory properties of adult stem cells to control the loss of elasticity and damage in the small airways seen in patients with COPD. Cell Surgical Network is investigating the effects of SVF (rich in mesenchymal stem cells and growth factors) on airway healing. We use a protocol that includes a combination of intravenous and nebulized SVF delivery. The deployment protocol performed under local anesthesia is all done as an outpatient at the time of SVF harvesting and procurement. The entire cellular surgical procedure takes approximately 3 hours.

Chronic Obstructive Pulmonary Disease (COPD) Call to Action

We care about our Chronic Obstructive Pulmonary Disease (COPD) patients at Cell Surgical Network and take pride in the time we provide to our patients to deploy the best protocols to help our patients achieve their goals. By filling out our Confidential Candidate Application, we will answer the questions and concerns you may have about Cell Surgical Network protocols for Chronic Obstructive Pulmonary Disease (COPD). Our Cell Surgical Network has Treatment Centers in several states.  Locate the nearest Treatment Center using Our Physician Network Map.

Follow Us

Visit Us On FacebookVisit Us On YoutubeVisit Us On LinkedinVisit Us On TwitterVisit Us On GooglePlus

Join us for our next webinar!

Select a date that works for you!
CLICK FOR DETAILS >>

Stem Cells and the FDA

Stem cell treatment is not approved by the FDA for any specific disease.
CLICK FOR DETAILS >>

Blog Posts